ArticleEClinicalMedicine2026
Metabolic effects of metyrapone treatment in patients with mild autonomous cortisol secretion: a prospective proof-of-concept trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment.Frontiers in endocrinology · 2026Article
- Adverse cardio-metabolic risk profile and epicardial adiposity in patients with adrenal adenoma: a cross-sectional study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mild autonomous cortisol secretion (MACS) is associated with an increased morbidity and mortality. Treatment options range from adrenalectomy to conservative management of comorbidities, but evidence on the effects of medical treatment is scarce. We therefore aimed to investigate the metabolic effects of evening metyrapone treatment in patients with MACS. Methods: We did a prospective, open-label, proof-of-concept trial (EudraCT: 2022-000161-40). Patients with uni-or bilateral adrenal incidentaloma and MACS defined by cortisol >1·8 μg/dL after 1 mg-dexamethasone-suppression-testing without clinical signs of Cushing's syndrome were included. Participants were investigated at baseline and after 12 weeks of treatment with metyrapone (500 mg at 6 p.m. and 250 mg at 10 p.m.). Intrahepatic lipid content (IHL) and abdominal visceral/subcutaneous fat mass were measured by magnetic resonance spectroscopy and imaging. Resting blood pressure measurements and blood sampling before and during an oral glucose tolerance test were conducted. IHL was the primary outcome parameter. Wilcoxon-signed-rank-tests were used for statistical analysis. Findings: Between May 2023 and September 2024, 19 patients were enrolled. Fifteen patients were included in the final analysis (12 female, median age 59 years [IQR 53-64]; median BMI 28 kg/m Interpretation: Treatment of MACS with evening doses of metyrapone lowers hepatic lipid content and improves the metabolic risk profile and might offer a novel therapeutic approach. Funding: Esteve (formerly HRA pharma) to the Medical University of Vienna (PI:PW).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.